Pricing Log in Create free account
Friday 6 November 2026 Export SNN’s income statement to Excel — free account

Smith & Nephew SNATS, Inc.

SNN Healthcare Medical Devices

Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.

31.12 0.89 −2.78%
Market cap
$13.4B
P/E
38.9×
Fwd P/E
18.9×
Dividend yield
2.49%
F-score
7/9
Altman Z
3.49
Beneish M
−2.70
Dividend safety
61/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Smith & Nephew SNATS, Inc. (SNN) EBITDA

Alert me on EBITDA

Smith & Nephew SNATS, Inc.'s EBITDA for fiscal 2025 was $1.4B, unchanged from fiscal 2024. Over the past ten years it has ranged from $857.0M (fiscal 2020) to $1.4B (fiscal 2017); the current reading is higher than 91% of that period. EBITDA has risen for 3 consecutive fiscal years. Smith & Nephew SNATS, Inc. ranks 7th of 147 Medical Devices companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $1.4B 4.99%
FY2024 $1.3B 17.51%
FY2023 $1.1B 3.84%
FY2022 $1.1B (8.02%)
FY2021 $1.2B 35.36%
FY2020 $857.0M (34.93%)
FY2019 $1.3B 1.46%
FY2018 $1.3B (6.01%)
FY2017 $1.4B 9.26%
FY2016 $1.3B 12.76%

Against its own ten years

Low $857.0M High $1.4B
Ten-year median $1.3B
Current reading's percentile 91

EBITDA against peers

Company EBITDA
SNN Smith & Nephew SNATS, Inc. $2.6B
GMED Globus Medical, Inc. compare $932.9M
PODD Insulet Corporation compare $693.3M
PEN Penumbra, Inc. compare $209.4M
BRKR Bruker Corporation compare $158.7M
TXG 10x Genomics compare −$40.4M
BIO.B Bio-Rad Laboratories, Inc. compare −$61.9M
BIO Bio-Rad Laboratories, Inc. compare −$61.9M
GKOS Glaukos Corporation compare −$130.8M

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on SNN